In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Dako designs test to predict benefit of ImClone drug

Executive Summary

Dako Corp. (cancer diagnostics) will develop an epidermal growth factor receptor (EGFr) screening kit that will used to identify those tumors that may benefit from treatment with ImClone Systems' IMC-C225, a monoclonal antibody designed to target and block EGFr.
Deal Industry
  • Biotechnology
    • Large Molecule
    • Large Molecule
      • Antibodies
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Disease Management
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal

Related Companies